Skip to Content
Children who have
juvenile idiopathic arthritis (JIA) are first treated
with nonsteroidal anti-inflammatory drugs (NSAIDs) that
often provide relief and reduce inflammation. NSAIDs are considered the
first-line treatment for JIA. Second-line drug therapy—known interchangeably as
disease-modifying antirheumatic drugs (DMARDs) and as slow-acting antirheumatic
drugs (SAARDs)—for JIA may be recommended when a child continues to have joint
pain, swelling, or both despite rest, exercise, use of NSAIDs, and physical
DMARDs/SAARDs include azathioprine,
cyclosporine, etanercept, methotrexate, and sulfasalazine.
a lot in common.
Although these medicines are often called
"disease-modifying," it has been hard to prove that they truly prevent
long-term joint damage. But they often relieve pain and swelling.
ByHealthwise StaffPrimary Medical ReviewerSusan C. Kim, MD - PediatricsSpecialist Medical ReviewerJohn Pope, MD - Pediatrics
Current as ofSeptember 9, 2014
Current as of:
September 9, 2014
Susan C. Kim, MD - Pediatrics & John Pope, MD - Pediatrics
How this information was developed to help you make better health decisions.
To learn more, visit Healthwise.org
© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
© Copyright 2015 Rush-Copley Medical Center • 2000 Ogden Avenue; Aurora, IL 60504
Main: 630-978-6200 • Physician Referral & Information: 630-978-6700 or 866-4COPLEY (866-426-7539)